On April 15, 2025 Baylink Biosciences reported that new preclinical data from its portfolio will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting from April 25-30, 2025, in Chicago, IL (Press release, Baylink Biosciences, APR 15, 2025, https://www.baylinkbio.com/post/lorem-ipsum-dolor-sit-amet-consectetur-adipiscing-elit [SID1234652037]). These data provide insights into the potential of Baylink’s innovative Antibody Drug Conjugate platform in treatment of cancers with high unmet medical need. Scientists at Baylink have invented a platform technology that enables the delivery of a variety of payloads including hydrophobic chemotherapy and protein degrader drugs at a high drug to antibody ratio while preserving stability and pharmacokinetic characteristics to enable application in ADC format. The innovative linker panel combined with Baylink’s proprietary payloads create a deep well of products, including dual payload ADC designs, and Degrader Antibody Conjugates (DAC) with potential application in cancer treatment.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Preclinical data from Baylink’s most advanced candidate (BLB-101) will be presented. BLB-101 is an antibody drug conjugate designed to target Claudin 6/9 and deliver the topoisomerase 1 inhibitor, exatecan in a highly efficient manner with a drug to antibody ratio of 8. Claudin 6 (CLDN6) is a tight junction protein that is highly expressed in various human cancers, including ovarian cancer, endometrial cancer, and non-small cell lung cancer (NSCLC), but is absent in normal adult tissues. Claudin 9 (CLDN9), which shares high homology with CLDN6, exhibits a similar expression pattern—being nearly undetectable in normal tissues but upregulated in ovarian and endometrial cancers.
Data generated to support the rationale for Baylink’s innovative linker platform will also be presented. Baylink’s linker platform is designed to reduce non-specific uptake into healthy tissues and cells while enhancing potency by improving ADC’s homogeneity, stability, PK, and efficacy. The platform also has the ability to deliver ADCs with multiple payload classes.
"We are very pleased to share these results from Baylink’s innovative antibody drug conjugate platform. The data presented at this year’s AACR (Free AACR Whitepaper) meeting demonstrate the potential for Baylink’s technology to overcome critical challenges in the ADC field," said Alice Chen, PhD, Chief Scientific Officer and Founder of Baylink. "In addition to sharing details on our platform technology, we are presenting data for one of our lead products, BLB-101, a novel antibody targeting CLDN6/9, conjugated to our linker BL001 delivering exatecan. We believe BLB-101 offers the potential for best in class performance for CLDN6/9+ tumors such as ovarian, endometrial, and lung cancer."
A linker platform for antibody drug conjugates (ADCs): expanding the therapeutic window
Poster number：7463
Session Date and Time: April 30, 2025, 9:00 AM – 12:00 PM
Preclinical evaluation of BLB-101, a topoisomerase-inhibitor-based anti-CLDN6/9 antibody-drug conjugate featuring a proprietary hydrophilic linker
Poster number：1578
Session Date and Time: April 28, 2025, 9:00 AM – 12:00 PM
About Baylink Biosciences innovative linker technology
Baylink’s linker technology was designed to overcome key challenges in the antibody drug conjugate field such as tumor resistance, lack of payload diversity, and narrow therapeutic window. Using proprietary, innovative linker designs, Baylink scientists created a panel of linkers enabling delivery of challenging drug payloads. Drugs that are hydrophobic in nature are problematic for delivery using traditional ADC linker technology. Baylink scientists incorporated design features into the linker technology that allows conjugation of these hydrophobic payloads with high DAR. Additionally, the linker technology effectively reduces non-tumor-antigen-specific uptake into healthy tissues and cells reducing potential for adverse events. The overall resulting ADCs have potential for better efficacy and safety. The platform is also enabling delivery of multiple payloads, so called dual payload ADCs.